Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Jul 26 04:00PM ET
65.98
Dollar change
+1.30
Percentage change
2.01
%
Index- P/E- EPS (ttm)-0.94 Insider Own7.05% Shs Outstand110.27M Perf Week29.63%
Market Cap7.28B Forward P/E- EPS next Y-1.48 Insider Trans-9.41% Shs Float102.50M Perf Month39.23%
Income-96.75M PEG- EPS next Q-0.24 Inst Own72.99% Short Float14.73% Perf Quarter-4.18%
Sales0.00M P/S- EPS this Y-7.57% Inst Trans-0.29% Short Ratio4.00 Perf Half Y206.74%
Book/sh8.31 P/B7.94 EPS next Y-50.87% ROA-14.36% Short Interest15.10M Perf Year362.04%
Cash/sh8.55 P/C7.72 EPS next 5Y40.00% ROE-14.80% 52W Range8.28 - 99.41 Perf YTD254.54%
Dividend Est.- P/FCF- EPS past 5Y-18.89% ROI-10.50% 52W High-33.63% Beta1.00
Dividend TTM- Quick Ratio37.69 Sales past 5Y0.00% Gross Margin- 52W Low696.86% ATR (14)4.82
Dividend Ex-Date- Current Ratio37.69 EPS Y/Y TTM-3.58% Oper. Margin0.00% RSI (14)65.57 Volatility9.37% 7.53%
Employees27 Debt/Eq0.00 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price113.55
Option/ShortYes / Yes LT Debt/Eq0.00 EPS Q/Q-3.81% Payout- Rel Volume2.42 Prev Close64.68
Sales Surprise- EPS Surprise23.84% Sales Q/Q- EarningsJul 24 AMC Avg Volume3.78M Price65.98
SMA2022.54% SMA5016.04% SMA20053.70% Trades Volume9,158,727 Change2.01%
Date Action Analyst Rating Change Price Target Change
Jun-27-24Initiated Morgan Stanley Overweight $105
May-16-24Upgrade Raymond James Outperform → Strong Buy $115 → $116
Mar-26-24Reiterated Oppenheimer Outperform $116 → $138
Mar-07-24Initiated Jefferies Buy $110
Feb-28-24Reiterated Oppenheimer Outperform $46 → $116
May-31-23Resumed ROTH MKM Buy $32
Mar-28-23Reiterated Maxim Group Buy $15 → $25
Mar-17-23Initiated Stifel Buy $22
Jul-29-21Resumed BTIG Research Buy $20
May-25-21Downgrade Raymond James Strong Buy → Outperform $27 → $12
Today 04:07PM
01:55PM
11:03AM
10:38AM
07:37AM
07:06PM Loading…
Jul-25-24 07:06PM
04:11PM
01:14PM
12:13PM
12:03PM
12:01PM
12:01PM
11:24AM
11:03AM
09:44AM
09:29AM Loading…
09:29AM
06:28AM
05:00AM
Jul-24-24 04:05PM
Jul-22-24 09:20AM
Jul-21-24 06:59AM
Jul-20-24 06:00AM
Jul-19-24 05:45PM
09:51AM
05:50AM
Jul-18-24 05:50PM
07:00AM
Jul-17-24 04:12PM
04:05PM
10:47AM
08:45AM Loading…
08:45AM
07:25AM
Jul-12-24 06:08AM
Jul-11-24 05:42AM
Jul-10-24 06:41AM
Jul-08-24 12:32PM
Jul-06-24 08:00AM
Jul-03-24 11:11AM
Jul-02-24 11:06AM
Jul-01-24 08:15AM
07:45AM
Jun-30-24 06:53AM
Jun-29-24 08:50PM
08:48PM
08:45PM
08:43PM
08:40PM
08:37PM
08:35PM
08:32PM
08:28PM
08:26PM
06:30PM
Jun-28-24 10:09AM
06:00AM
05:50AM
Jun-27-24 04:09PM
Jun-26-24 05:50PM
07:45AM
Jun-24-24 07:33AM
Jun-20-24 05:50PM
Jun-18-24 08:34AM
07:50AM
Jun-17-24 05:50AM
Jun-15-24 09:31AM
07:45AM
Jun-14-24 05:50AM
Jun-13-24 05:45PM
09:30AM
Jun-12-24 10:00AM
Jun-11-24 06:52AM
Jun-10-24 09:45AM
Jun-09-24 08:45AM
Jun-08-24 07:40AM
Jun-07-24 05:45PM
02:52AM
Jun-06-24 05:23PM
07:45AM
Jun-05-24 10:28AM
09:42AM
Jun-04-24 04:17PM
01:36PM
08:00AM
07:46AM
07:05AM
06:00AM
Jun-03-24 10:15AM
09:00AM
May-31-24 05:45PM
06:00AM
06:00AM
05:33AM
May-30-24 04:03PM
May-29-24 06:30AM
May-28-24 09:30AM
May-27-24 06:58PM
06:13PM
May-26-24 08:31AM
May-25-24 12:00PM
08:15AM
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
ZANTE GREGChief Financial OfficerMay 03 '24Option Exercise4.8634,249166,285241,610May 03 08:51 PM
ZANTE GREGChief Financial OfficerMay 03 '24Sale74.6966,7564,986,008174,854May 03 08:51 PM
Mancini MariannaChief Operating OfficerMay 01 '24Option Exercise6.18281,4251,740,575629,933May 02 09:27 PM
Mancini MariannaChief Operating OfficerMay 01 '24Sale78.66281,42522,136,474348,508May 02 09:27 PM
Lian BrianPresident & CEOFeb 09 '24Sale29.9045,0001,345,5002,139,882Feb 09 08:59 PM
Lian BrianPresident & CEOFeb 08 '24Option Exercise3.76189,079711,3672,404,882Feb 08 07:40 PM
Rouan Sarah KathrynDirectorFeb 08 '24Option Exercise8.3225,000208,00025,000Feb 08 07:38 PM
Lian BrianPresident & CEOFeb 08 '24Sale26.87269,0797,230,7842,184,882Feb 08 07:40 PM
Rouan Sarah KathrynDirectorFeb 08 '24Sale28.0525,000701,2500Feb 08 07:38 PM
Lian BrianPresident & CEOJan 31 '24Option Exercise1.2385,000104,5502,349,882Jan 31 08:39 PM
Lian BrianPresident & CEOJan 31 '24Sale24.7185,0002,100,7502,264,882Jan 31 08:39 PM
Lian BrianPresident & CEOJan 30 '24Option Exercise1.2335,00043,0502,299,882Jan 30 09:05 PM
Lian BrianPresident & CEOJan 30 '24Sale23.9535,000838,2502,264,882Jan 30 09:05 PM
Rouan Sarah KathrynDirectorJan 19 '24Option Exercise8.3230,000249,60030,000Jan 19 08:35 PM
Rouan Sarah KathrynDirectorJan 19 '24Sale23.0530,000691,5000Jan 19 08:35 PM
ZANTE GREGChief Financial OfficerJan 04 '24Sale17.9015,000268,500180,730Jan 04 09:35 PM